All updated as on -
The predicted term for the hyperimmune globulins market is from 2024 to 2031, and it will develop at a CAGR of 8.8%. Forecasts indicate that the market will reach a value of 3,166.79 million USD by 2031, up from 1,767.12 million USD in 2023 and 1,877.36 million USD in 2024.
Plasma from vaccinated donors is used to make hyperimmune globulins, which are polyclonal antibodies. Their passive protection against particular diseases is a result of the large titers of antibodies they possess, which target specific antigens. These goods include a wide variety of antibodies in different amounts since they are polyclonal. In order to prevent infections like varicella, hepatitis B, rabies, tetanus, botulism, and tetanus after exposure, hyperimmune globulins are frequently administered.
Hyperimmune globulins are lifesavers in situations where patients can't make their own antibodies or when they're sick and need to stop the toxic effects of their illness right away. Patients who have been exposed to a disease but do not have an adequate immune response, which could cause consequences, can benefit from hyperimmune globulins. Many people who get serious illnesses would die considerably sooner if hyperimmune globulins weren't available.
Patients obtain passive immunity against certain pathogens after receiving hyperimmune globulin. In contrast to the active immunity provided by intravenous immunoglobulins (IVIGs), which is ideal in situations where an individual is exposed to a living pathogen or is injected with a material containing antigen, such as the rabies vaccine, this passive immunity provides protection against the disease immediately but only for a brief period of time. Vaccines typically take a lot longer to accomplish that goal, but hyperimmune globulin offers passive and immediate, but temporary, immunity. Among the many agents that can be protected against by hyperimmune globulins are tetanus toxin, varicella-zoster, rabies, and hepatitis B.
If a patient is unable to produce antibodies, if they have already contracted an illness and need to mitigate the effects of any associated toxins, or if they have been exposed to an illness but do not mount a sufficient immune response, hyperimmune globulin passive immunization is the best course of action. Many people who get fatal illnesses would not make it if hyperimmune globulins weren't available.
The vast majority of the approximately 380 plasma collection centers in the US are operated by plasma treatment manufacturers; these centers have been accredited by the International Quality Plasma Program and are licensed by the US Food and Drug Administration. Donors can provide plasma up to twice a week, far more often than whole blood donors, who can only give once every eight weeks. It is anticipated that the market share of hyperimmune globulins will be enhanced if the number of voluntary plasma donations experiences a substantial increase. Additionally, the global hyperimmune globulins market will have favorable growth through 2027, thanks to an increase in disease outbreaks including SARS, MERS, COVID-19, and others.
A comprehensive analysis of the market, including quantitative and qualitative data, is included in the research. It summarizes and predicts the worldwide market based on several segments. Also included are the five main regions' market sizes and forecasts for 2019–2028: North America, Europe, Asia–Pacific (APAC), MEA, and South and Central America. We next break down the global hyperimmune globulin market by country and subsegment. Along with the present trend and potential in the region, the paper analyzes and predicts outcomes for eighteen countries worldwide.
Using a supply-and-demand perspective, the study examines market dynamics (drivers, constraints, opportunities, and future trends) that will impact the market throughout the forecast period. After looking at the political, economic, social, and technological aspects of the Hyperimmune Globulin market in each of the five regions—North America, Europe, Asia-Pacific, Middle East and Africa, and South and Central America—the research gives a thorough PEST analysis for each area.
Report Coverage
Global Hyperimmune Globulins research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Hyperimmune Globulins report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Hyperimmune Globulins competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Hyperimmune Globulins market players and analyses their core competencies in each global market sub-segments.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Hyperimmune Globulins market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Hyperimmune Globulins market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Grifols, S.A., ADMA Biologics, Inc., Octapharma AG, Kedrion, Shanghai RAAS Blood Products Co., Ltd., EMERGENT, Biotest AG., CSL Behring, Kamada Pharmaceuticals., GigaGen and Saol Therapeutics
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2031. INFINITIVE DATA EXPERT has segmented the global Hyperimmune Globulins market based on the below-mentioned segments:
Global Hyperimmune Globulins Market, By Product Type
Immunoglobulins for Hepatitis B
Immunoglobulins For Rabies
Immunoglobulins for Tetanus
Rho (D) Immunoglobulins
Others
Global Hyperimmune Globulins Market, By End User
Government Institutions
Private Sector
Others
Global Hyperimmune Globulins market, Regional Analysis
Plasma from vaccinated donors is used to make hyperimmune globulins, which are polyclonal antibodies. Their passive protection against particular diseases is a result of the large titers of antibodies they possess, which target specific antigens. These goods include a wide variety of antibodies in different amounts since they are polyclonal. In order to prevent infections like varicella, hepatitis B, rabies, tetanus, botulism, and tetanus after exposure, hyperimmune globulins are frequently administered.
Hyperimmune globulins are lifesavers in situations where patients can't make their own antibodies or when they're sick and need to stop the toxic effects of their illness right away. Patients who have been exposed to a disease but do not have an adequate immune response, which could cause consequences, can benefit from hyperimmune globulins. Many people who get serious illnesses would die considerably sooner if hyperimmune globulins weren't available.
Patients obtain passive immunity against certain pathogens after receiving hyperimmune globulin. In contrast to the active immunity provided by intravenous immunoglobulins (IVIGs), which is ideal in situations where an individual is exposed to a living pathogen or is injected with a material containing antigen, such as the rabies vaccine, this passive immunity provides protection against the disease immediately but only for a brief period of time. Vaccines typically take a lot longer to accomplish that goal, but hyperimmune globulin offers passive and immediate, but temporary, immunity. Among the many agents that can be protected against by hyperimmune globulins are tetanus toxin, varicella-zoster, rabies, and hepatitis B.
If a patient is unable to produce antibodies, if they have already contracted an illness and need to mitigate the effects of any associated toxins, or if they have been exposed to an illness but do not mount a sufficient immune response, hyperimmune globulin passive immunization is the best course of action. Many people who get fatal illnesses would not make it if hyperimmune globulins weren't available.
The vast majority of the approximately 380 plasma collection centers in the US are operated by plasma treatment manufacturers; these centers have been accredited by the International Quality Plasma Program and are licensed by the US Food and Drug Administration. Donors can provide plasma up to twice a week, far more often than whole blood donors, who can only give once every eight weeks. It is anticipated that the market share of hyperimmune globulins will be enhanced if the number of voluntary plasma donations experiences a substantial increase. Additionally, the global hyperimmune globulins market will have favorable growth through 2027, thanks to an increase in disease outbreaks including SARS, MERS, COVID-19, and others.
A comprehensive analysis of the market, including quantitative and qualitative data, is included in the research. It summarizes and predicts the worldwide market based on several segments. Also included are the five main regions' market sizes and forecasts for 2019–2028: North America, Europe, Asia–Pacific (APAC), MEA, and South and Central America. We next break down the global hyperimmune globulin market by country and subsegment. Along with the present trend and potential in the region, the paper analyzes and predicts outcomes for eighteen countries worldwide.
Using a supply-and-demand perspective, the study examines market dynamics (drivers, constraints, opportunities, and future trends) that will impact the market throughout the forecast period. After looking at the political, economic, social, and technological aspects of the Hyperimmune Globulin market in each of the five regions—North America, Europe, Asia-Pacific, Middle East and Africa, and South and Central America—the research gives a thorough PEST analysis for each area.
Report Coverage
Global Hyperimmune Globulins research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Hyperimmune Globulins report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Hyperimmune Globulins competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Hyperimmune Globulins market players and analyses their core competencies in each global market sub-segments.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2031 |
| Base Year | 2023 |
| Forecast Period | 2023-2031 |
| Historical Period | 2017-2021 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Grifols, S.A., ADMA Biologics, Inc., Octapharma AG, Kedrion, Shanghai RAAS Blood Products Co., Ltd., EMERGENT, Biotest AG., CSL Behring, Kamada Pharmaceuticals., GigaGen and Saol Therapeutics |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Hyperimmune Globulins Market from 2021 to 2031.
- Market Forecast for Hyperimmune Globulins Market from 2021 to 2031.
- Regional Market Share and Revenue from 2021 to 2031.
- Country Market share within region from 2021 to 2031.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Hyperimmune Globulins competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Hyperimmune Globulins
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Hyperimmune Globulins market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Hyperimmune Globulins market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Grifols, S.A., ADMA Biologics, Inc., Octapharma AG, Kedrion, Shanghai RAAS Blood Products Co., Ltd., EMERGENT, Biotest AG., CSL Behring, Kamada Pharmaceuticals., GigaGen and Saol Therapeutics
Primary Target Market
- Market Players of Hyperimmune Globulins
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2031. INFINITIVE DATA EXPERT has segmented the global Hyperimmune Globulins market based on the below-mentioned segments:
Global Hyperimmune Globulins Market, By Product Type
Immunoglobulins for Hepatitis B
Immunoglobulins For Rabies
Immunoglobulins for Tetanus
Rho (D) Immunoglobulins
Others
Global Hyperimmune Globulins Market, By End User
Government Institutions
Private Sector
Others
Global Hyperimmune Globulins market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive hyperimmune globulins market market research and competitor analysis for your business to help you develop more profound insights into the hyperimmune globulins market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the hyperimmune globulins market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.